Skip to main content

$0.155 -0.005 (-3.13%)

High

$0.17

Low

$0.16

Trades

36

Turnover

$26,369

Volume

167,225
30 June 2023 at 4:10pm
Register to track LGP and receive email alerts.

Ethics approval for CBD Phase III clinical trial

StockBot

416,823 posts

LGP released this announcement to the ASX on 30 November 2022, 10:03. The announcement is marked as price sensitive, and is 3 page(s) in length and 257.9kb in size.

You can view all announcements from LGP and see how they appear on a price chart on the announcements page.

At the date of this announcement, LGP was 0.006% short sold according to ASIC data. It was ranked the 560th most shorted stock on the ASX. It remains ranked 643rd as of the latest reported data (10 February 2025).

Other Recent Announcements from LGP
Annual Report to shareholders 30 June 2023, 9:38
Corporate Governance Statement and Appendix 4G 30 June 2023, 8:47
Preliminary Final Report 31 May 2023, 10:16
Ethics approval for CBD Phase III clinical trial 30 November 2022, 10:03
Half Yearly Report and Accounts 30 November 2022, 9:52
LGP wins National Export Award for International Health 25 November 2022, 10:00
LGP significantly expands flower portfolio 24 November 2022, 8:58
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track LGP and receive email alerts.